Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus Hexanic Extract of Serenoa Repens Versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

June 2022 in “ Journal of Clinical Medicine ”

Antonio Alcaraz, David Castro‐Díaz, Mauro Gacci, Andrea Salonia, Vincenzo Ficarra, Joaquı́n Carballido, A. Rodrı́guez-Antolı́n, José Medina‐Polo, J.M. Fernández Gómez, J.M. Cózar-Olmo, Santiago Búcar-Terrades, Noemí Pérez-León, Francisco Brenes-Bermúdez, José Molero, Antonio Fernández-Pro-Ledesma, Michael Herdman, J.C. Angulo, J. Dalmau, on behalf of the QUALIPROST Study Group

tamsulosin hexanic extract of Serenoa repens 5-alpha-reductase inhibitors benign prostatic hyperplasia lower urinary tract symptoms IPSS score HESr 5ARI BPH

Studysummary This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review

34 citations , December 2021 in “Journal of Clinical Medicine”

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

research The Risk of Venous Thromboembolism in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors

6 citations , August 2021 in “Clinical Epidemiology”

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

research Association Between 5-Alpha Reductase Inhibitor Use and the Risk of Depression: A Meta-Analysis

3 citations , August 2020 in “Urology Journal”

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

research Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm

17 citations , January 2020 in “The World Journal of Men's Health”

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis

research Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis

66 citations , April 2017 in “International Journal of Andrology”

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

research Association of Suicidality and Depression With 5α-Reductase Inhibitors

90 citations , March 2017 in “JAMA Internal Medicine”

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

research 5α-Reductase Inhibitors Increase Acute Coronary Syndrome Risk in Patients with Benign Prostate Hyperplasia

6 citations , March 2015 in “Journal of Endocrinological Investigation”

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia

research A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia

22 citations , August 2014 in “Clinical endocrinology”

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations , December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.